Delisting risk
Xenetic Biosciences
Develops DNase-based adjuncts for cancer therapy and armored CAR-T treatment.
$3.98
After-hours close+0.02 (+0.51%)
At close$3.96(−0.25%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders 4.36%
Shares outstanding 2.29M · Float 2.21M · 96.3% free float
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Renaissance Technologies LLC | 6.00% | 137.4K | 13G | May 14, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| James F. Parslow | officer: Interim CEO and CFO | 100.0K | 4.36% | Apr 23, 2026 |
2 ten-percent owners hold 13.7K shares by Form 4, outside the officers-and-directors figure above · 4 people have not refiled in the last 18 months (30.7K shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.